Published in J Intern Med on December 07, 2016
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood (2006) 8.33
A note on quantifying follow-up in studies of failure time. Control Clin Trials (1996) 7.96
Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed (2004) 5.11
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97
The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med (2013) 2.32
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol (2008) 1.90
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol (2003) 1.81
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood (2007) 1.67
Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. Leuk Lymphoma (2010) 1.61
Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. Leuk Res (2010) 1.47
Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood (2005) 1.30
No increase in age-specific incidence of myelodysplastic syndromes. Haematologica (2004) 1.27
Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw (2013) 1.12
Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol (2013) 0.99
Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need. Transfusion (2012) 0.94
Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw (2015) 0.92
Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions. Eur J Haematol (2011) 0.89
Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol (2015) 0.88
High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol (2013) 0.82
Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes. Leuk Res (2011) 0.79
Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution. Am J Hematol (2013) 0.79
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. Leuk Res (2014) 0.84
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. Leuk Res (2015) 0.78
Management of Chronic Lymphocytic Leukemia (CLL) in the Elderly: A Position Paper from an International Society of Geriatric Oncology (SIOG) Task Force. Ann Oncol (2016) 0.75
Preferred and actual place of death in haematological malignancy. BMJ Support Palliat Care (2015) 0.75